Candesartan drug interactions

Candesartan
ATACAND® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packages
Clinical Trials on Candesartan
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Drug Interactions

Because candesartan is not significantly metabolized by the cytochrome P450 system and at therapeutic concentrations has no effects on P450 enzymes, interactions with drugs that inhibit or are metabolized by those enzymes would not be expected.

Non-Steroidal Anti-Inflammatory Agents including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors)

In patients who are elderly, volume-depleted (including those on diuretictherapy), or with compromised renal function, co-administration of NSAIDs, including selective COX-2 inhibitors, with angiotensinII receptor antagonists, including candesartan, may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible. Monitor renal function periodically in patients receiving candesartan and NSAID therapy.

The antihypertensive effect of angiotensinII receptor antagonists, including candesartan may be attenuated by NSAIDs including selective COX-2 inhibitors.

Lithium

Reversible increases in serum lithiumconcentrations and toxicity have been reported during concomitant administration of lithiumwith ACE inhibitors, and with some angiotensinII receptor antagonists. An increase in serum lithiumconcentration has been reported during concomitant administration of lithiumwith ATACAND. Monitor serum lithiumlevels.

Dual Blockade of the Renin-angiotensin System (RAS)

Dual blockade of the RAS with angiotensinreceptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on ATACAND and other agents that affect the RAS.

Do not co-administer aliskiren with ATACAND in patients with diabetes. Avoid use of aliskiren with ATACAND in patients with renal impairment (GFR <60 ml/min) [seeCONTRAINDICATIONS (4)].

References

{{angiotensinII receptor antagonists}}

[[Category:angiotensinII receptor antagonists]]